-- Zhejiang Huahai Pharmaceutical's (SHA:600521) attributable profit slid 76% to 266.9 million yuan in 2025 from 1.12 billion yuan in 2024, according to a Wednesday filing with the Shanghai bourse.
Earnings per share at the drug manufacturer decreased 77% to 0.18 yuan from 0.77 yuan in the previous year.
Operating income declined 10% year over year to 8.59 billion yuan from 9.55 billion yuan.
Shares increased 2% during morning trading on Wednesday.